238 related articles for article (PubMed ID: 33609353)
1. Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.
Goetgebuer RL; Kreijne JE; Aitken CA; Dijkstra G; Hoentjen F; de Boer NK; Oldenburg B; van der Meulen AE; Ponsioen CIJ; Pierik MJ; van Kemenade FJ; de Kok IMCM; Siebers AG; Manniën J; van der Woude CJ; de Vries AC
J Crohns Colitis; 2021 Sep; 15(9):1464-1473. PubMed ID: 33609353
[TBL] [Abstract][Full Text] [Related]
2. Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
Kreijne JE; Goetgebuer RL; Erler NS; De Boer NK; Siebers AG; Dijkstra G; van Kemenade FA; Hoentjen F; Oldenburg B; van der Meulen AE; Ponsioen CIJ; Pierik MJ; van der Woude CJ; de Vries AC;
Aliment Pharmacol Ther; 2023 Jul; 58(2):207-217. PubMed ID: 37221820
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study.
Rungoe C; Simonsen J; Riis L; Frisch M; Langholz E; Jess T
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):693-700.e1. PubMed ID: 25086189
[TBL] [Abstract][Full Text] [Related]
6. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
7. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
8. Risk evaluation for the development of cervical intraepithelial neoplasia: development and validation of risk-scoring schemes.
Lee CH; Peng CY; Li RN; Chen YC; Tsai HT; Hung YH; Chan TF; Huang HL; Lai TC; Wu MT
Int J Cancer; 2015 Jan; 136(2):340-9. PubMed ID: 24841989
[TBL] [Abstract][Full Text] [Related]
9. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
10. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
11. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
13. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
14. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
15. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
16. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
18. Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study.
Fröberg M; Östensson E; Belkić K; Oštrbenk A; Poljak M; Mints M; Arbyn M; Andersson S
Cancer; 2019 Jan; 125(2):239-248. PubMed ID: 30536370
[TBL] [Abstract][Full Text] [Related]
19. Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.
Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Johnson Jones ML; Whitney E; Pemmaraju M; Brackney M; Abdullah N; Scahill M; Dahl RM; Cleveland AA; Unger ER; Markowitz LE;
Clin Infect Dis; 2019 Apr; 68(8):1282-1291. PubMed ID: 30137283
[TBL] [Abstract][Full Text] [Related]
20. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
